Information on EC 2.4.1.102 - beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase

Word Map on EC 2.4.1.102
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
2.4.1.102
-
RECOMMENDED NAME
GeneOntology No.
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R = UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hexosyl group transfer
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
mucin core 1 and core 2 O-glycosylation
-
-
Mucin type O-glycan biosynthesis
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
UDP-N-acetyl-D-glucosamine:O-glycosyl-glycoprotein (N-acetyl-D-glucosamine to N-acetyl-D-galactosamine of beta-D-galactosyl-(1->3)-N-acetyl-D-galactosaminyl-R) 6-beta-N-acetyl-D-glucosaminyltransferase
The enzyme is involved in O-glycosylation of several proteins, such as mucins.
CAS REGISTRY NUMBER
COMMENTARY hide
87927-97-7
-
95978-15-7
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
BoHV-4, gene Bo17
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
LSL-KrasG12D/+ and p48Cre/+ mice
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
malfunction
metabolism
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
UDP-GlcNAc + (Galbeta1-3GalNAcalpha1-)TAGV
UDP + (Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TAGV
show the reaction diagram
-
pH 7.0, 0.2 mM, 1250% activity
-
-
?
UDP-GlcNAc + 4-nitrophenyl 2-(acetylamino)-2-deoxy-3-O-beta-D-galactopyranosyl-alpha-D-galactopyranoside
UDP + 4-nitrophenyl 2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-6)-[beta-D-galactopyranosyl-(1-3)]-2-(acetylamino)-2-deoxy-alpha-D-galactopyranoside
show the reaction diagram
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-G-(Galbeta1-3GalNAcalpha1-)TTTPIST-NH2
UDP + Ac-G-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-G-(Galbeta1->3GalNAcbeta1->)TTTPIST-NH2
UDP + Ac-G-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTTPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 75% activity
-
-
?
UDP-GlcNAc + Ac-GT-(Galbeta1-3GalNAcalpha1-)TTPIST-NH2
UDP + Ac-GT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-GT-(Galbeta1->3GalNAcbeta1->)TTPIST-NH2
UDP + Ac-GT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 150% activity
-
-
?
UDP-GlcNAc + Ac-GTT-(Galbeta1-3GalNAcalpha1-)TPIST-NH2
UDP + Ac-GTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-GTT-(Galbeta1->3GalNAcbeta1->)TPIST-NH2
UDP + Ac-GTT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-P-(Galbeta1-3GalNAcalpha1-)TTTGIST-NH2
UDP + Ac-P-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTGIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 50% activity
-
-
?
UDP-GlcNAc + Ac-P-(Galbeta1-3GalNAcalpha1-)TTTPIST-NH2
UDP + Ac-P-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-P-(Galbeta1->3GalNAcbeta1->)TTTGIST-NH2
UDP + Ac-P-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTTGIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 200% activity
-
-
?
UDP-GlcNAc + Ac-P-(Galbeta1->3GalNAcbeta1->)TTTPIST-NH2
UDP + Ac-P-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTTPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 175% activity
-
-
?
UDP-GlcNAc + Ac-PT-(Galbeta1-3GalNAcalpha1-)TTGIST-NH2
UDP + Ac-PT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTGIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 300% activity
-
-
?
UDP-GlcNAc + Ac-PT-(Galbeta1-3GalNAcalpha1-)TTPIST-NH2
UDP + Ac-PT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 200% activity
-
-
?
UDP-GlcNAc + Ac-PT-(Galbeta1->3GalNAcbeta1->)TTGIST-NH2
UDP + Ac-PT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTGIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 95% activity
-
-
?
UDP-GlcNAc + Ac-PT-(Galbeta1->3GalNAcbeta1->)TTPIST-NH2
UDP + Ac-PT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 185% activity
-
-
?
UDP-GlcNAc + Ac-PTT-(Galbeta1-3GalNAcalpha1-)TGIST-NH2
UDP + Ac-PTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TGIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 200% activity
-
-
?
UDP-GlcNAc + Ac-PTT-(Galbeta1-3GalNAcalpha1-)TPIST-NH2
UDP + Ac-PTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-PTT-(Galbeta1->3GalNAcbeta1->)TPIST-NH2
UDP + Ac-PTT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TPIST-NH2
show the reaction diagram
-
pH 7.0, 0.2 mM, 10% activity
-
-
?
UDP-GlcNAc + AP-(Galbeta1-3GalNAcalpha1-)TSS
UDP + AP-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TSS
show the reaction diagram
-
pH 7.0, 0.2 mM, 250% activity
-
-
?
UDP-GlcNAc + T-(Galbeta1-3GalNAcalpha1-)TTVTPTPTG
UDP + T-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTVTPTPTG
show the reaction diagram
-
pH 7.0, 0.2 mM, 75% activity
-
-
?
UDP-GlcNAc + TT-(Galbeta1-3GalNAcalpha1-)TVTPTPTG
UDP + TT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TVTPTPTG
show the reaction diagram
-
pH 7.0, 0.2 mM, 75% activity
-
-
?
UDP-GlcNAc + TTTV -(Galbeta1-3GalNAcalpha1-)TPTPTG
UDP + TTTV -(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPTPTG
show the reaction diagram
-
pH 7.0, 0.2 mM, 75% activity
-
-
?
UDP-GlcNAc + TTTVTP-(Galbeta1-3GalNAcalpha1-)TPTG
UDP + TTTVTP-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPTG
show the reaction diagram
-
pH 7.0, 0.2 mM, 50% activity
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
show the reaction diagram
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
show the reaction diagram
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
show the reaction diagram
UDP-N-acetyl-D-glucosamine + antifreeze glycoprotein polypeptide
?
show the reaction diagram
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + asialo-alpha1 acid glycoprotein
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + asialo-blood group A negative PSM
?
show the reaction diagram
-
acceptor contains no fucose
-
-
?
UDP-N-acetyl-D-glucosamine + asialo-submaxillary mucin
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + asialofetuin
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + asialoglycophorin A
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + benzyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
show the reaction diagram
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-(CH2)8CO2Me
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-(CH2)8CO2Me
show the reaction diagram
-
synthetic disaccharide
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
show the reaction diagram
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
show the reaction diagram
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methylumbelliferyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methylumbelliferyl
show the reaction diagram
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
show the reaction diagram
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
show the reaction diagram
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
show the reaction diagram
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
show the reaction diagram
UDP-N-acetyl-D-glucosamine + D-fucosyl-beta-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + D-fucosyl-beta-1,3-(N-acetyl-D-glucosaminyl beta-1,6)-N-acetyl-alpha-D-galactosaminyl-benzyl
show the reaction diagram
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + fetuin
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
show the reaction diagram
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-methyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-methyl
show the reaction diagram
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
show the reaction diagram
UDP-N-acetyl-D-glucosamine + Galbeta(1-3)GalNAcalpha-p-nitrophenol
?
show the reaction diagram
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + Galbeta(1-3)GalNAcalpha-p-nitrophenol
UDP + ?
show the reaction diagram
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + Galbeta1,3GalNAc-O-p-nitrophenyl
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + Galbeta1,3GalNAcalpha1-p-nitrophenyl
?
show the reaction diagram
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + Galbeta1-3GalNAcalpha-4-nitrophenyl
?
show the reaction diagram
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + glycoprotein gp180
UDP + N-acetyl-beta-D-glucosaminyl-glycoprotein gp180
show the reaction diagram
UDP-N-acetyl-D-glucosamine + N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-alpha-D-galactosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,3)-N-acetyl-alpha-D-galactosaminyl-R
show the reaction diagram
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + p-nitrophenyl 2-acetamido-2-deoxy-3-O-(beta-D-galactopyranosyl)-alpha-D-galactopyranoside
?
show the reaction diagram
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + phenyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
show the reaction diagram
UDP-N-acetyl-D-glucosamine + trachea mucin
?
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
show the reaction diagram
Q09324
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
12-O-tetradecanoylphorbol-13-acetate
-
about 10fold decreased activity, down-regulation of native enzyme in KM3 leukemia cell line, but not of the recombinant enzyme; i.e. TPA
5,5'-dithiobis-2-nitrobenzoic acid
-
inactivation is partially prevented by prior addition of donor or acceptor substrate and by sulfhydryl reducing agents. 1 mM inhibits 94%
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
and other nitrophenyl-sugar-derivatives; strong inhibition under UV-radiation at 350 nm, specific for substrate binding site, preincubation with beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl partially protects
Ca2+
-
slight inhibition
diethyldicarbonate
-
0.2 mM, 74% inhibition
EDTA
-
slight inhibition
Hydroxyphenylglyoxal
-
19% inhibition at 0.25 mM, complete inhibition at 5-10 mM
iodoacetate
-
0.2 mM inhibits the enzyme 70%
jacalin
core 1 O-glycan-specific lectin from Artocarpus integrifolia, differing sensitivity of different BoHV-4 mutants to jacalin-mediated neutralization, overview
-
N-bromosuccinimide
-
5 mM, complete inhibition
NEM
-
inactivation is partially prevented by prior addition of donor or acceptor substrate and by sulfhydryl reducing agents. 0.2 mM inhibits 42%
substrate analogues lacking the 6-hydroxyl of the N-acetylgalactosamine
-
weak
-
talniflumate
-
Triton X-100
-
activation at 0.1% v/v, inhibition at higher concentrations, pig stomach
tunicamycin
-
inactivation; prevents secretion of recombinant enyzme from Sf9 cells
uridine
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2-mercaptoethanol
-
stimulates up to 20fold
cytokines
-
induction by IL-4 and IL-12/STAT4
-
dithiothreitol
-
stimulates up to 20fold
Empigen BB
-
activation, detergent
sodium butyrate
-
induction after treatment of cells for 24 h, 16fold increase in activity, blocked by actinomycin D and cycloheximide
Triton X-100
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2 - 5.5
3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
3.1 - 10
4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
23
antifreeze glycoprotein polypeptide
-
-
-
5.2
asialo-blood group A negative PSM
-
-
-
12 - 37
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
0.8 - 2
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
0.36 - 0.43
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
2
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
AML cell line
0.6
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
AML cell line
10
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
-
AML cell line
0.77
galactosyl-beta-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
-
-
4.2
galactosyl-beta-1,3-N-acetyl-alpha-D-galactosaminyl-methyl
-
-
1.2
galactosyl-beta-1,3-N-acetyl-alpha-D-galactosaminyl-phenyl
-
-
0.92
galactosyl-beta-1,3-N-acetyl-beta-D-galactosaminyl-p-nitrophenyl
-
-
1.2
galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
-
0.86
galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-alpha-o-nitrophenyl
-
-
0.52
galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-alpha-p-nitrophenyl
-
-
0.11 - 1.6
Galbeta(1-3)GalNAcalpha-p-nitrophenol
5.2
porcine submaxillary mucin polypeptide
-
0.0063 - 5.6
UDP-N-acetyl-D-glucosamine
additional information
additional information
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.95 - 2.5
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
0.14 - 0.26
UDP
0.23
UMP
-
mutant enzyme C217S, in 50 mM Tris (pH 7.5), at 37C
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.0000048
-
normal granulocytes
0.0000056
-
untreated recombinant KM3 leukemia cell line
0.000013
-
unstimulated normal T-lymphocytes
0.00002
-
CML granulocytes
0.00004
-
EBV B-cell line from healthy individuals
0.000087
-
AML cells
0.00015
-
undifferentiated CaCo-2, colonic adenocarcinoma, cells
0.00034
-
CaCo-2, colonic adenocarcinoma, cells differentiated to enterocytes
0.00067
-
recombinant enzyme in Panc1-MUC1 cells
8.2
-
mutant enzyme C217S
9.2
-
wild-type enzyme
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.2
-
-
7.4
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6.7 - 7.8
-
broad optimum
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
differential expression of GCNT3 gene among tumour samples from stage II colon cancer patients by quantitative reverse-transcription PCR, overview
Manually annotated by BRENDA team
-
maturation of dendritic cells leads to a rapid change in the expression of glycosyltransferases involved in O-linked glycosylation. A down-regulation of C2GnT1 mRNA and enzymatic activity is observed with a concurrent up-regulation of ST3Gal I and ST6GalNAc II mRNA resulting in a loss of the core 2 structures required for sLex expression as a P-selectin ligand
Manually annotated by BRENDA team
-
expression of C2GnT1 in 84 cases of endometrioid-type endometrial carcinoma, 15 cases of endometrial hyperplasia, and 30 normal endometria, immunohistochemic analysis, overview. C2GnT1 is strongly expressed at the invasive tumour front in several cases
Manually annotated by BRENDA team
-
NCI498, ileo-caecal carcinoma cell line
Manually annotated by BRENDA team
-
transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
Manually annotated by BRENDA team
-
erythroleukemia cell line
Manually annotated by BRENDA team
-
pre-B lymphocytic leukemia cell line
Manually annotated by BRENDA team
-
colonic adenocarcinoma cell line
Manually annotated by BRENDA team
-
YC2C2 lymphocytic leukemia cell line
Manually annotated by BRENDA team
-
colonic grade II tumour cell line
Manually annotated by BRENDA team
-
colonic grade III tumour cell line
Manually annotated by BRENDA team
-
colonic large ulcerating grade IV tumour cell line, low activity
Manually annotated by BRENDA team
-
CD8 T cell
Manually annotated by BRENDA team
high content
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
secretion into medium of the recombinant enzyme from Sf9 cells
-
Manually annotated by BRENDA team
additional information
-
isozyme C2GnT-M targets the Golgi at the Giantin site and is recycled by binding to non-muscle myosin IIA, a motor protein, via the cytoplasmic tail. C2GnT-M forms a complex with Giantin before KRT1, demonstrating CT-mediated sequential events of Golgi targeting and retention of C2GnT-M
-
Manually annotated by BRENDA team
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
70000
-
gel filtration
additional information
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
dimer
the monomer units of the observed dimer C2GnT possesses the GT-A fold and are connected by a disulfide bond between the Cys235 residues, quantum mechanical/molecular modeling using enzyme crystal structures, PDB IDs 2GAK and 2GAM, as templates. The structure of C2GnT contains two regions; the first (38-121) is composed of alpha-helices. The second region, which corresponds to the catalytic domain (122-428), is an alpha/beta/alpha structure consisting of a central six-stranded mixed beta-sheet. Four disulfide bonds are found in each monomer (Cys151-Cys199, Cys372-Cys381, Cys59-Cys413, and Cys100-Cys172), the remaining Cys217 is unpaired and located in the donor binding site. C2GnT may occur in an open conformation, and a closed conformation. The location of the C2GnT-conserved Glu320 residue structurally corresponds to the catalytic base found in other glycosyltransferases with the GT-A fold
monomer
additional information
-
in absence of dithiothreitol, one of the two free Cys residues (Cys217 and Cys235) is found to be engaged in an intermolecular bridge causing dimerization of the protein
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
phosphoprotein
-
phosphorylation increases actvity
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
C217S mutant in complex with UDP, hanging drop vapor diffusion method, using 24% (w/v) polyethylene glycol 4000, 0.1 M glycine (pH 9.0) and 0.6 M LiCl
-
hanging drop vapor diffusion method, X-ray crystal structures of murine C2GnT-L in the absence and presence of the acceptor substrate Galbeta1,3GalNAc at 2.0 and 2.7 A resolution, respectively
-
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
freeze-drying and resuspension in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 95% remaining activity
-
freeze-thawing, after 2 cycles 13% loss of activity
-
OXIDATION STABILITY
ORGANISM
UNIPROT
LITERATURE
inactivation during storage may be caused by air oxidation and points to a requirement for inmodified thiols in the core protein
-
659276
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-70C, crude enzyme extract, stable up to 1 year
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-80C, stable for at least 6 months, wild-type enzyme
-
4C, stable in solution or after lyophilization for several months
-
frozen in liquid nitrogen, several months
-
mutant enzyme C217S can be stored at 4C for at least 3 months without any loss of activity, wild-type enzyme loses about 95% of its activity after 4 weeks
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
IgG-Sepharose bead chromatography
-
partially, recombinant from Sf9 insect cells
-
pilot scale, recombinant protein A-tagged enzyme, fluidized bed system
-
recombinant
-
recombinant as GST fusion protein from a bacterial expression system
-
single-step, affinity chromatography on UDP-hexanolamine Sepharose
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
CHO cells stably transfected with a pSEcTag plasmid, This plasmid contains bC2GnT-M cDNA devoid of the 5'-sequence coding the cytoplasmic tail and transmembrane domain
-
cloning and expression of isozyme 3 in Spodoptera frugiperda Sf9 insect cells via baculovirus infection, secretion of the enzyme; coexpression of isozyme 3 with leukosialin as substrate in CHO cells for in vivo activity assay of the enzyme; DNA sequence determination and analysis
expression in human pancreatic cancer cell line Panc1-MUC1, which lacks enzyme C2GnT activity, alters the expression of MUC1-epitope in the same cell line
-
expression in PC12 cells
-
expression in Spodoptera frugiperda Sf9 insect cells via baculovirus infection, truncated enzyme form
-
expression of the soluble catalytic domain in insect cells
-
functional expression in CHO cells, direction of enzyme activity onto the cell surface, a soluble chimeric enzyme form shows also core 4 6beta-GalNAc transferase activity, DNA and amino acid sequence determination
gene Bo17, DNA and amino acid sequence determination and analysis, two different mRNAs are encoded by the Bo17 gene of all available BoHV-4 strains. While the first one corresponds to the entire coding sequence of the Bo17 gene, the second results from the splicing of a 138-bp intron encoding critical residues of the enzyme. The first one is enzymatically active, the second is inactive and results from the alternative splicing of the region encoding the catalytic site of the enzyme, enzyme activities in infected cells, overview
gene GCNT1 , recombinant expression in CHO-K1 cells. Glycosylation-related genes in CHO-K1 cells are present, but strictly suppressed and regulated. CHO cells are transiently co-transfected with plasmids encoding extended C1 beta3GnT3, C2 beta6GnT1, or C3 beta3GnT6 with or without ST6Gal I or CHST4, respectively, and resulting O-glycan and core chain spectrum, overview
gene GCNT2, recombinant expression in COS7 cells
-
gene GCNT3 expression analysis in pancreatic cancer and in healthy pancreatic tissue, gene expression profiling and transcriptome analysis
gene GCNT3, quantitative reverse-transcription PCR enzyme expression analysis
HH and BW5147 cells are transfected with either wild-type or mutant human C2GnT-I cDNA. Expression of C2GnT-I makes HH cells susceptible to galectin-1
-
mutant enzymes are expressed in HEK-293T cells
-
overexpression in CHO cells as protein A-tagged fusion protein
-
overexpression in KM3 leukemia cell line
-
recombinant expression of C-terminally c-Myc-tagged betaC2GnT-M in Panc1 cells, transient expression of GFP-tagged C2GnT-M in HeLa cells. Yeast two-hybrid analysis of the interactions between KRT1 protein head, tail, or rod domain and the cytoplasmic peptides of hC2GnT-M
-
the recombinant protein generated by mC2GnT-M cDNA exhibits core 2, core 4, and blood group I enzyme activities with a ratio of 1.00:0.46:1.05
-
transfection in COS-7 cells
-
transfection into CD99 or mock transfectants
-
transfection into JKT-1 cells
-
wild-type and mutant enzymes expressed in CHO-K1 cells
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
activation-induced enzyme up-regulation under permissive (T helper type 1) conditions is strongly reduced by cyclosporin A
-
inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro
interleukin-12 induces enzyme expression
-
no expression in normal pancreatic tissue
-
the three chemotherapeutic agents, with different mechanism of action, 5-fluorouracil, bortezomib and paclitaxel significantly induce GCNT3 expression in several cancer cells, but not in drug-unreponsive cells
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
C100S
-
mutant enzyme with 10% of wild-type activity
C151S
-
inactive mutant protein
C172S
-
inactive mutant protein
C199S
-
inactive mutant protein
C217S
-
mutant enzyme with 41% of wild-type activity. Similar Km and Vmax values for Galbeta(1-3)GalNAcalpha-p-nitrophenol, Km-value for UDP-N-acetyl-D-glucosamine is 2.9fold higher than wild-type value. In contrast to wild-type enzyme, the mutant enzyme is not inhibited by sulfhydryl reagents and is not stimulated by reducing agents
C372S
-
inactive mutant protein
C381S
-
inactive mutant protein
C413S
-
inactive mutant protein
C59S
-
inactive mutant protein
DELTA407-428
-
inactive mutant protein
T60A/T97A
K401A/C217S
-
inactive
R378A/C217S
-
inactive
R378A/K401A/C217S
-
inactive
S158C
-
mutation reduces C2GnT activity but does not affect substrate specificity or enzyme dimerization. Mutation appears to result in haploinsufficiency of C2GnT activity. C2GnT-I haploinsufficiency is sufficient for loss of core 2 O-glycan expression and galectin-1 resistance
additional information
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
diagnostics
medicine
molecular biology
-
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl and other nitrophenyl-sugar-derivatives are useful as specific inhibitors and as affinity label
synthesis
-
chemical-enzymatic synthesis of sialyl-Lex-containing hexasaccharides found on O-linked glycoproteins, process involves several enzymes of the pathway